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Mouse embryonic ﬁbroblastCaspases are key effectors of programmed cell death. Down- and up-regulation of their activity are involved in dif-
ferent pathologies. In most cells, zVAD-fmk prevents apoptosis. However, unexpected effects of zVAD-fmk have
been characterized in different laboratories, cell models and cell death processes. We have previously shown
that zVAD-fmk accelerates p53-dependent apoptosis in rat embryonic ﬁbroblasts. In this study, we pursued our
investigations on zVAD-fmk effects and focused our study at the mitochondrial level in mouse embryonic ﬁbro-
blasts (MEFs). In both primary and immortalized (by AgT or 3T9 protocol) MEFs, zVAD-fmk increased
etoposide-induced loss of ΔΨm. This increase correlated with an increase of the number of apoptotic cells in pri-
mary and 3T9 MEFs, but did not in AgT MEFs. In both types of immortalized MEFs, zVAD-fmk regulated neither
p53 levels nor transcriptional activities, suggesting that zVAD-fmk acts downstream of p53. In MEFs, zVAD-fmk
increased p53-dependent loss of ΔΨm, cytochrome c release and caspase-9 activity. Indeed, zVAD-fmk inhibited
effector caspases (caspases-3, -6, -7) as expected but increased caspase-9 cleavage and activity in etoposide-
treated MEFs. Q-VD-OPh, another caspase inhibitor, also increased both loss of ΔΨm and caspase-9 cleavage in
etoposide-treated MEFs. Invalidation of bax and bak suppressed p53-dependent cell death and zVAD-fmk regula-
tion of this process. Invalidation of caspase-9 did not inhibit mitochondrial membrane depolarization but
suppressed zVAD-fmk ampliﬁcation of this process. Altogether, our data suggest that caspase-9 activity is up-
regulated by zVAD-fmk and is involved in an ampliﬁcation loop of etoposide-induced cell death at the mitochon-
drial level in MEFs.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Programmed cell death (PCD) is a physiological process required for
embryogenesis, metamorphosis, tissue homeostasis and elimination of
cells that are potentially detrimental to the organism. Misregulation of
PCD has been implicated in many pathologies, such as cancers, neuro-
degenerative and autoimmune diseases [1,2]. Different types of PCD
have been described including apoptosis, necrosis and autophagy,
which diverge on criteria such as the initiating death signals, morpho-
logical alterations, mitochondrial events, protease and/or nuclease acti-
vations, as well as functional and immunological aspects [3,4]. We
focused our study on mitochondrial-dependent cell death induced by
the tumor suppressor p53. In response to stresses such as DNA dam-
ages, oncogene activation or hypoxia, the transcription factor p53 in-
duces the intrinsic pathway of apoptosis [5,6] by trans-activating
genes encoding proteins involved in the induction of apoptosis, suchet Biologie Cellulaire, EA4589
France. Tel.: +33 1 39253658;
rights reserved.as proapoptotic Bcl‐2 family members (Bax, Puma or noxa) [7,8].
These proteins as well as p53 itself [9] can induce mitochondrial modi-
ﬁcations, such as mitochondrial internal membrane depolarization and
outer membrane permeabilization. These modiﬁcations induce the
release of apoptogenic proteins, including cytochrome c and Smac/
DIABLO, from the mitochondrial inter-membrane space to the cytosol.
Cytochrome c release results in the formation of the apoptosome, a
large complex composed of cytochrome c, ATP/dATP, Apaf‐1 and
procaspase‐9. The formation of this apoptosome requires the interac-
tion of Apaf‐1 and procaspase‐9 via their respective CARD domain,
and activates the initiator caspase‐9, which in turn activates effector
caspases (caspase‐3, -6 and ‐7) [10,11]. Smac/DIABLO cooperates to
the regulation of the apoptotic process by neutralizing the caspase‐3,
-7, -9 inhibitor XIAP in the cytosol [12,13]. In some cell types, p53 also
regulates the extrinsic apoptotic pathway by controlling the expression
of genes coding for death receptor family members. This pathway is
activated by death receptors able to cross-activate the intrinsic pathway
via the caspase‐8-dependent cleavage of Bid, a proapoptotic Bcl‐2 fam-
ily member [14].
A molecular hallmark of apoptosis is the activation of caspases, cyste-
inyl proteases that execute cell death through the cleavage of a broad
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ptotic caspases can be classiﬁed as initiator (caspase‐2, -8, -9, -10) or ef-
fector caspases (caspase‐3, -6, -7). The classical apoptotic pathways
require a sequential activation of initiator caspases (requiring adapter
proteins) and effector caspases (cleaved by activated initiator or effector
caspases). Most of the studies on both the function and the regulation
of caspases have been performed using pharmacological inhibitors [18].
Benzyloxycarbonyl-Val-Ala-Asp(OMe)-ﬂuoromethylketone (zVAD-fmk)
is the most used cell permeable broad-caspase inhibitor. In most of the
cells, zVAD-fmk prevents the apoptotic process. However, we have previ-
ously shown that zVAD-fmk increases p53-dependent cell death in rat
embryonic ﬁbroblasts [19–21]. In REtsAFs, a rat embryonic ﬁbroblast
cell line immortalized with a temperature-sensitive mutant (tsA58) of
the simian virus 40 large tumor antigen (AgT), we have shown that
p53-dependent cell death in the presence of zVAD-fmk diverges from
the classical pathway. This cell death process induced in the presence of
zVAD-fmk could not be inhibited by Bcl-2 overexpression, in contrast to
the classical pathway [19,21]. Furthermore, we have shown that zVAD-
fmk could modify p53-transcriptional activities in these cells. Indeed,
p53-dependent trans-activation was decreased while p53-dependent
trans-repression was increased in the presence of zVAD-fmk as shown
by the study of p53 target gene expression and microarray analysis [20].
Different laboratories presented evidences that zVAD-fmk can induce
switches between apoptotic, necrotic and autophagic cell deaths [22,23]
and that zVAD-fmk cannot prevent all types of caspase-dependent apo-
ptosis [19–21,24,25]. These unexpected effects of zVAD-fmk were
detected on different cell death pathways, in different cell types and
after different cell death stimuli. Altogether, these results suggest that
the inability of zVAD-fmk to prevent some apoptotic cell deaths or to in-
duce a switch in the cell death process might be due to the fact that this
inhibitor does not inhibit all caspases to the same extent. To test this hy-
pothesis and to progress in the comprehension of zVAD-fmk effect on
p53-dependent cell death, we pursued our investigations on the zVAD-
fmk effect in mouse embryonic ﬁbroblasts (MEFs), in primary cultures
and in immortalized cell lines issued from wild type, Bax−/− Bak−/−
and caspase-9−/− mice. In the present study, we show that: (i) zVAD-
fmkacceleratesmitochondrialmembranedepolarization and cytochrome
c release occurring during etoposide-induced cell death; (ii) although
zVAD-fmk classically inhibited effector caspases, it did not inhibit the ini-
tiator caspase-9 but in contrast it induced the accumulation of the active
form of this caspase; and (iii) caspase-9 induces a mitochondrial ampliﬁ-
cation loop during etoposide-induced cell death in MEFs.2. Materials and methods
2.1. Cell culture and drugs
Primary cultures of mouse embryonic ﬁbroblasts (primary MEFs)
were a generous gift from Alice Jouneau (INRA, Jouy-en-Josas,
France). Established cell lines from wild type (3T9 MEFs) and Bax−/−
Bak−/− (DKO 3T9MEFs)mouse embryonic ﬁbroblasts were a generous
gift from Peter Daniel (Clinical and Molecular Oncology, University
Medical Center Charité, Berlin, Germany). SV40 Antigen T immortalized
MEFs from wild type (AgT MEFs) and Caspase-9−/− (C9KO AgT MEFs)
micewere a generous gift fromRichard Flavell (Yale School ofMedicine,
Department of Immunology, New Haven, USA). MEFs were cultured in
Dulbecco's modiﬁed Eagle's medium (DMEM, Invitrogen) sup-
plemented with 10% (3T9, AgT, C9KO AgT and primary MEFs, HeLa
cells) or 15% (DKO 3T9 MEFs) fetal bovine serum (FBS), 100 U/ml pen-
icillin, 100 μg/ml streptomycin and 1% Glutamax at 37 °C in 5% CO2 hu-
midiﬁed atmosphere. Etoposide (50 μg/ml, Sigma), which is an
inhibitor of Topoisomerase II and a DNA damage-inducing drug, was
used to induce p53-dependent cell death. zVAD-fmk (50 μM, Z-Val-
Ala-DL-Asp-ﬂuromethylketone, Bachem) and Q-VD-OPh (20 μM,
Quinolyl-Val-Asp-OPh, Biovision) were used as caspase inhibitors.2.2. Flow cytometry analysis of cell death
Cellswere plated in 12-well plates at a density of 7.104cells/ml. At 70%
conﬂuence, different treatments (etoposide, zVAD-fmk and/or Q-VD-
OPh) were performed. Both attached and ﬂoating cells were collected
and analyzed by ﬂow cytometry after DiOC6(3) and propidium iodide
(PI) staining as previously described [26]. Three parameters were exam-
ined: the DiOC6(3) staining (representative of the mitochondrial mem-
brane potential, ΔΨm), cell size (representative of the condensation of
the cells), and the PI staining (representative of primary or secondary
necrotic cells). In this study, we focused our attention on: cells with low
ΔΨm which correspond to cells with low DiOC6(3) and low PI staining
cells; and, apoptotic cells which correspond to cells with small cell size,
low DiOC6(3) and low PI staining cells. MitoTracker® Red CMXRos was
used to analyze the mitochondrial membrane potential of transfected
cells. Cells were incubated with 150 nM MitoTracker® Red CMXRos for
30 min at 37 °C before ﬂow cytometry analysis.
2.3. ROS production analysis by ﬂow cytometry
3T9 MEFs cells and HeLa cells were plated in 12-well plates at a
density of 7.104cells/ml. At 70% conﬂuence, etoposide and/or zVAD-
fmk treatments were performed and reactive oxygen species (ROS)
production was evaluated by ﬂow cytometry after DCFH-DA staining
as previously described (Dumay et al., 2006).
2.4. RT-PCR assay
At 70% conﬂuence, 3T9 MEFs were incubated with or without
etoposide+/−zVAD-fmk. After 16 h of treatment, total RNAwas isolated
using the guanidium isothiocyanate method. RT-PCR was performed to
examine the levels of p53,mdm2, p21 and noxamRNAs as previously de-
scribed [26]. RT‐PCR of 18S rRNA was used as a control.
2.5. Cytosol fraction preparation
At 70% conﬂuence, 3T9 MEFs were incubated with etoposide+/−
zVAD-fmk for different treatment times (0, 4, 8, 12, 16 and 19 h). At-
tached and ﬂoating cells were collected and centrifuged 5 min at
200 g. Pellets were resuspended in 200 μL of Lysis buffer (10 mM
Hepes–KOH pH 7.4, 0.1 mM EDTA, 1 mM EGTA, 250 mM sucrose,
1 mM protease inhibitor cocktail AEBSF (Roche)). After 30 min incuba-
tion at 4 °C, cell disruptionwas completed by passing the cells through a
0.4×20 mm needle 10 times. 1/3 of the extract was conserved as the
total extract, 2/3 of the extract was centrifuged for 5 min at 4 °C at
52 g to eliminate nuclei. The supernatant was further centrifuged
30min at 4 °C at 7000 g to eliminate mitochondria and reticulum. The
supernatant corresponded to the cytosol fraction and was analyzed by
Western blot.
2.6. Western blot analysis
At 70% conﬂuence, MEFs were incubated with or without etoposide,
zVAD-fmk and/or Q-VD-OPh. After different treatment times, cells were
harvested, lysed and frozen at−20 °C. Proteins (10–30 μg), from total
cell extracts or from cytosolic extracts, were separated in NuPAGE 4–
12% Bis–Tris polyacrylamide gels according to the manufacturer's in-
structions (Invitrogen) and transferred onto a PVDF membrane
(Millipore). The primary antibodies used were anti‐p53 (Pab 122, gift
from E. May, IRSC, Villejuif, France), anti-phospho‐p53 (Ser-15, Cell Sig-
naling), anti-actin (Sigma), anti-cytochrome c (BD Pharmigen), anti-
VDAC (gift from C. Brenner, UVSQ, Versailles, France), anti-lamin A/C
(Cell Signaling), anti-enolase (gift from N. Lamande, College de France,
Paris), anti-caspase‐9 (5B4, Abcam), anti-cleaved caspase‐3 (Asp175,
Cell Signaling), anti-cleaved caspase-6 (Asp162, Cell Signaling), and
anti-tubulin (MAS078, Sera-Lab). Secondary antibodies (peroxidase-
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(Biosystem). Immunoreactive bands were detected by chemilumines-
cence using the Immobilon kit (Millipore).
2.7. Immunocytochemistry
3T9 MEFs were plated onto glass coverslips in complete medium.
At 60% conﬂuence, cells were incubated with or without etoposide
and/or zVAD-fmk. Immunocytochemistry analysis was performed as
previously described [26]. In the present study, we used a mouse
monoclonal anti-cytochrome c (BD Bioscience) as primary antibody
and a FITC-conjugated anti-mouse antibody (Jackson Immuno-
Research Laboratory) as secondary antibody. Nuclei were stained
with Hoechst 33342. Immunolabeled cells were examined by epi-
ﬂuorescence under a DMR Leica microscope equipped with an Olym-
pus DP70 photo camera using the DP Manager software.
2.8. Caspase-3/7 and caspase-9 activity assays
The Apo-ONE™ Homogeneous Caspase‐3/7 Assay and the Caspase‐
Glo™ 9 Assay (Promega) were used to detect caspase‐3/-7 and
caspase‐9 activities in 3T9 MEFs treated with etoposide+/−zVAD-
fmk according to the manufacturer's instructions.
2.9. Cell transfection
Caspase-9 KO AgT MEFs were plated in 12‐well plates for ﬂow
cytometry analysis, and in 60 mm diameter plates for Western-blot
analysis at a density of 105cells/ml. At 80% conﬂuence, cells were trans-
fected with 125 ng (for 12-well plate) or 1 μg (for 60 mm plate)
pCDNA3-caspase‐9 expression vector in the presence of Lipofectamine™
Transfection Reagent and PLUS™ Reagent in DMEM (Invitrogen) and in-
cubated for 5 h at 37 °C according to the manufacturer's instructions.
Human caspase-9 expression vector was a generous gift from Patrick
Melhen (Apoptosis, Cancer and Development Laboratory, Centre Léon
Bérard, Lyon, France). After 24 h of culture in complete medium, trans-
fected cells were incubated with etoposide for 16 h. Then, the mitochon-
drial membrane potential was analyzed by ﬂow cytometry after Mito
Tracker Red CMXRos staining and cell lysates were analyzed by
Western-blot as previously described.
2.10. Statistical analysis
Each bar of the different graphs indicates the average measure and
standard error of at least three independent experiments, and P-
values are from paired two-tailed Student's t-tests.
3. Results
3.1. zVAD-fmk increases etoposide-induced mitochondrial membrane
depolarization in MEFs
In order to test the effect of zVAD-fmk on p53-dependent apopto-
sis in mouse embryonic ﬁbroblasts (MEFs) that are either spontane-
ously immortalized (3T9 MEFs [27]), immortalized by transfection
of SV40 AgT (AgT MEFs) or not immortalized (primary MEFs), we
used etoposide, a DNA damage-inducing drug, to activate p53. The
cell death process induced by etoposide in the presence or absence
of zVAD-fmk was analyzed by ﬂow cytometry after DiOC6(3) and
propidium iodide (PI) staining (Fig. 1). Apoptotic cells corresponded
to the cells with three characteristics: low PI staining to exclude pri-
mary and secondary necrotic cells, low DiOC6(3) staining indicating
a low mitochondrial membrane potential ΔΨm, and low cell size
(i.e. condensating cells). In AgT MEFs, etoposide increased the per-
centage of apoptotic cells and the addition of zVAD-fmk classically
decreased this effect (Fig. 1A). In 3T9 MEFs and in primary MEFs,zVAD-fmk surprisingly increased the percentage of apoptotic cells
(Fig. 1B, C). The effect of zVAD-fmk was more pronounced (earlier
and higher) in primary MEFs than in the established cell line 3T9
MEFs, suggesting a physiological relevance of this process. Then, we
analyzed the percentage of cells with low ΔΨm (whatever the cell
size) in the three types of MEFs. zVAD-fmk increased the percentage
of cells with low ΔΨm in primary and immortalizedMEFs. Thus, these
results suggest that: (i) zVAD-fmk differently affected late events of
apoptosis, in particular cell condensation, depending on the immor-
talized state, and (ii) zVAD-fmk accelerates the decrease of mitochon-
drial membrane potential in the three types of MEFs by acting either
upstream or at the level of mitochondrial events.
zVAD-fmk has been reported to switch between different cell
death modes (apoptosis, necrosis, autophagy, …) [22,23,28]. In
etoposide-treated MEFs, zVAD-fmk did not signiﬁcantly increase ne-
crosis, autophagy and LEI/L-DNAse II caspase-independent cell
death (data not shown). Only apoptosis was detected to be regulated
by zVAD-fmk in this cellular model.
3.2. zVAD-fmk does not modify p53 transcriptional activity after
etoposide treatment in 3T9 MEFs
We have previously shown that zVAD-fmk modiﬁes both p53 sta-
bility and p53-transcriptional activities in rat embryonic ﬁbroblasts
[20,21]. Therefore, we examined the status of p53 (mRNA and protein
levels) and some of its targets (at the mRNA level) in the presence or
absence of etoposide and/or zVAD-fmk in mouse embryonic ﬁbro-
blasts. In 3T9 MEFs, addition of etoposide and/or zVAD-fmk did not
modify the levels of p53 mRNAs and protein (Fig. 2). In contrast, ad-
dition of etoposide induced an increase of the level in serine 15-
phosphorylated p53 (Fig. 2B) as well as in mdm2, p21 and noxa
mRNA levels (Fig. 2A), showing that etoposide induces p53-
transcriptional activity. The addition of zVAD-fmk modiﬁed neither
the p53 levels nor the mRNA levels of p53 targets in the presence of
etoposide, suggesting that zVAD-fmk does not regulate p53-
transcriptional activity in 3T9 MEFs. Altogether, these results suggest
that zVAD-fmk increases mitochondrial membrane depolarization
downstream of p53 transcriptional activity in mouse embryonic ﬁ-
broblasts after etoposide treatment.
3.3. Bax and/or Bak are involved in etoposide-induced cell death in the
presence or absence of zVAD-fmk
We then examined the possible involvement of Bax/Bak or reactive
oxygen species (ROS) accumulation in the cell death process occurring
in 3T9MEFs after etoposide treatment in the absence or in the presence
of zVAD-fmk.
To determine whether Bax and Bak are required for etoposide-
induced cell death and for the regulation of this process by zVAD-fmk,
we used DKO 3T9 MEFs (Bax−/−Bak−/− double knockout MEFs [29]).
Mitochondrial membrane depolarization, as assessed by ﬂow
cytometric ΔΨm analysis, induced by etoposide in the presence or ab-
sence of zVAD-fmk in 3T9 MEFs (after 16 h of treatment) was not
detected in DKO 3T9 MEFs even after longer treatments (16 and 45 h
of treatment) (Fig. 3A). Our results show that Bax and/or Bak are re-
quired for etoposide-induced loss of ΔΨm and for zVAD-fmk-induced
increase of this depolarization in mouse embryonic ﬁbroblasts.
ROS accumulation could be involved in mitochondrial-membrane
potential collapse and cell death. Thus, we examined ROS production
induced by etoposide in 3T9 MEF cells in the absence or presence of
zVAD-fmk by ﬂow cytometry after DCFH-DA staining. Whatever the
treatment (etoposide+/−zVAD-fmk), DCF positive 3T9 MEFs could
not be detected by ﬂow cytometry in contrast to DCF positive
etoposide-treated HeLa cells, which were used as positive control
(Fig. 3B). This result suggests that etoposide in the presence or absence
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Fig. 1. zVAD-fmk increases mitochondrial membrane depolarization in MEFs after etoposide treatment. AgT MEFs (A), 3T9 MEFs (B) and primary MEFs (C) were untreated or treat-
ed with etoposide, both etoposide and zVAD-fmk or zVAD-fmk. After 16 h (for AgT and 3T9 MEFs) or 12 h (for primary MEFs) of treatment, all the cells (attached and ﬂoating) were
analyzed by ﬂow cytometry after DiOC6(3) and PI staining. Apoptotic cells are characterized by a low PI staining to exclude primary and secondary necrotic cells, a low DiOC6(3)
staining that correlates with low mitochondrial membrane potential ΔΨm and a low cell size that reveals cell condensation and late apoptotic events. Cells with low ΔΨm display a
low PI and low DiOC6(3) staining whatever the size of the cells. Average and Student's t tests were performed to compared etoposide versus etoposide and zVAD-fmk (*pb0.05).
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3.4. zVAD-fmk increases cytochrome c release after etoposide-treatment
We then examined the release of cytochrome c frommitochondria to
the cytosol after etoposide-treatment in the presence or absence of
zVAD-fmk in 3T9 MEFs. Immunocytochemistry experiments show that
cytochrome c was principally detected in the mitochondria in the ab-
sence of cell death inducer (Fig. 4A, B). After etoposide treatment, cyto-
chrome c release to the cytosol was detected in about 10% of the cells.
The addition of zVAD-fmk increased the percentage of cells with cyto-
chrome c release in the presence of etoposide up to 34%. zVAD-fmkalone had no effect on cytochrome c localization. After etoposide treat-
ment in the presence or absence of zVAD-fmk, dying cells detached
from the Petri dish. Thus, we analyzed the level of cytosolic cytochrome
c in all cells (both attached and ﬂoating cells) after cytosolic extraction
and Western-blot analysis (Fig. 4C). The detection of cytosolic enolase
and the absence of detection of both mitochondrial VDAC and nuclear
lamin A/C in the cytosolic fractions conﬁrmed the efﬁciency of the en-
richment. All these proteins could be detected in total cell extracts (con-
trol lanes). The amount of cytochrome c detected in the cytosolic
fractions after etoposide treatment strongly increased in the presence
of zVAD-fmk. Thus, we have shown that zVAD-fmk increases cyto-
chrome c release after etoposide treatments in mouse embryonic ﬁbro-
blasts by two experimental processes.
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caspases after etoposide treatment
In most of the cells, cytochrome c release induced the formation of
the apoptosome and the activation of initiator caspase-9 and effector
caspases (‐3, -6 and ‐7). We studied the cleavage and activity status of
these caspases in 3T9 MEFs treated with etoposide and/or zVAD-fmk.
After etoposide treatment, cleaved forms of caspase‐9, caspase-3 and
caspase-6 were detected in 3T9 MEFs by Western-blot (Fig. 5A). Sur-
prisingly, the addition of zVAD-fmk in the presence of etoposide in-
creased the level of cleaved caspase-9, while zVAD-fmk modiﬁed
caspase-3 cleavage and inhibited caspase-6 cleavage. An upper
cleaved form of caspase-3 was detected in the presence of zVAD-
fmk, which probably corresponded to an incompletely cleaved form
of this caspase.
To determinewhether the cleaved forms of caspase-9 and caspases-
3 detected in the presence of etoposide and zVAD-fmkwere functional,
we measured caspase‐9 and caspase‐3/-7 activities. In 3T9 MEFs, the
etoposide treatment increased both caspase-9 (Fig. 5B) and caspase‐
3/-7 (Fig. 5C) activities. Adding zVAD-fmk down-regulated caspase‐
3/-7 activity but, in contrast, up-regulated caspase‐9 activity in mouse
embryonic ﬁbroblasts.
In most cells, caspase-6 is cleaved by active caspase-3. The absence
of caspase-6 cleavage in the presence of etoposide and zVAD-fmk in
3T9 MEFs (Fig. 5A) suggested that caspase-6 is cleaved by caspase-3
in etoposide-treated MEF cells and that zVAD-fmk inhibited
caspase-6 by inhibiting caspase-3. Etoposide treatment in the absenceof zVAD-fmk induced lamin A/C cleavage (a caspase-6 substrate) in
3T9 MEFs suggesting caspase-6 activation in this condition. Addition
of zVAD-fmk inhibited both etoposide-induced caspase-6 activity
and lamin A/C cleavage in 3T9 MEFs cells.
Altogether, our data showed that during etoposide-induced apop-
tosis, zVAD-fmk classically inhibited effector caspases in mouse em-
bryonic ﬁbroblasts but surprisingly, increased caspase-9 activity.
3.6. Q-VD-OPh increased etoposide-induced loss of ΔΨm and caspase-9
cleavage in 3T9 MEFS
We tested another broad-spectrum caspase inhibitor, Q-VD-OPh in
3T9 MEFs. As zVAD-fmk, Q-VD-OPh increased etoposide-induced loss
of mitochondrial membrane potential as assessed by ﬂow cytometry
analysis of ΔΨm (Figs. 1B, 3A, 6A). We also showed by Western-blot
(Fig. 6B) that Q-VD-OPh increased the level of etoposide-induced
cleaved caspase-9 and modiﬁed caspase-3 cleavage, to the same extent
as zVAD-fmk. Thus, using two different caspase inhibitors, zVAD-fmk
and Q-VD-OPh, we demonstrated a correlation between the loss of
ΔΨm and caspase-9 cleavage in 3T9 MEFs.
3.7. Caspase-9 activates an ampliﬁcation loop at the mitochondrial level
Our study suggests that caspase-9 is a key caspase in the mito-
chondrial membrane depolarization induced by etoposide in the
presence of zVAD-fmk in 3T9 MEFs. In an attempt to progress in the
characterization of its function, we analyzed the process induced by
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embryonic ﬁbroblast cell line issued from caspase-9 knock-out mice
(caspase-9−/− AgT MEFs).
First, we controlled that etoposide induces p53 transcriptional acti-
vity in caspase-9−/− AgT MEFs to the same extent as in control AgT
MEFs issued from wild type mice (Fig. 7A). Analysis by RT-PCR showed
that etoposide in the presence or absence of zVAD-fmk induced a simi-
lar increase of noxa, mdm2 and p21 mRNA levels in both cell lines.
Then, we examined the status of caspase-9 and caspase-3 in these
cell lines (Fig. 7B). In caspase-9−/− AgT MEFs, no proform or cleaved
caspase-9 was detected whatever the treatment in contrast to control
AgT MEFs. In these control cells, zVAD-fmk increased the level of
cleaved caspase-9 after etoposide treatment as previously shown in
3T9 MEFs. In caspase-9−/− AgT MEFs, we did not detect cleaved
caspase-3 whatever the treatment, showing that caspase-9 is required
for caspase-3 activation in MEFs cells after etoposide treatment.
We further analyzed mitochondrial membrane depolarization by
cytometry after DiOC6(3) and PI staining (Fig. 7C). Etoposide treat-
ment increased the percentage of cells loosing ΔΨm at a similar
level in both cell lines. The addition of zVAD-fmk in the presence of
etoposide increased this effect in AgT MEFs. In caspase-9−/− AgT
MEFs, the percentage of cells with a loss of ΔΨm after etoposide
treatment was not modiﬁed by the presence of zVAD-fmk. Thus, al-
though caspase-9 is not required for etoposide-dependent mitochon-
drial membrane depolarization, caspase-9 activity is required for the
ampliﬁcation of this process by zVAD-fmk.
To conﬁrm that caspase-9 can induce an increase of mitochondrial
membrane depolarization, we expressed caspase-9 in caspase-9−/−AgT MEFs by transfection and analyzed the loss of ΔΨm in the ab-
sence or in the presence of etoposide in transfected cells (Fig. 7D,
E). In the absence of etoposide, overexpression of caspase-9 (both
proform and cleaved forms could be detected) induced loss of ΔΨm
to the same extent as etoposide‐treated control cells. In the presence
of etoposide, cleaved caspase-9 level increased as well as loss of ΔΨm
induced in caspase-9 transfected cells. Thus, overexpression of
caspase-9 in caspase-9−/− AgT MEFs increased mitochondrial mem-
brane depolarization induced by etoposide. Altogether, our data
show that caspase-9, which was up-regulated by zVAD-fmk or by
transfection, induces an ampliﬁcation loop at the mitochondrial
level of the cell death process induced by etoposide in MEFs.
4. Discussion
In the present study, we examined the effect of zVAD-fmk in
etoposide-induced cell death in mouse embryonic ﬁbroblasts and
showed that zVAD-fmk can regulate this cell death process at the mito-
chondrial level. Indeed, zVAD-fmk increased etoposide-induced mito-
chondrial membrane depolarization in MEFs, whether the cells were
immortalized (3T9 and AgT MEFs) or not (Figs. 1 and 7). The effect of
zVAD-fmk on ΔΨm was correlated with an increase in the number of
apoptotic cells in primary and 3T9 MEFs. This correlation was not
detected in AgT MEFs. However, longer etoposide treatment in the pre-
sence of zVAD-fmk induced late events of apoptosis, like cell size reduc-
tion and DNA fragmentation (data not shown). Our results suggest that
immortalization of MEFs by the AgT could modify the level and/or the
activity of factors involved in late events of the apoptotic process
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modiﬁcations remain to be characterized.
In both immortalized MEFs (AgT and 3T9 MEFs), zVAD-fmk modi-
ﬁed neither p53 mRNA and protein levels nor p53 transcriptional ac-
tivities (in particular the trans-activation of noxa, mdm2 and p21)
induced in the presence of etoposide (Figs. 2 and 7). The regulations
of p53-transcriptionnal activities induced by zVAD-fmk characterized
in rat embryonic ﬁbroblasts [20] were not detected in MEFs. These
differences between both cellular models could reﬂect either diffe-
rences in cellular contents between rat and mouse, or differences in
the p53 induction mode (etoposide treatment in MEFs versus tempe-
rature increase in REtsAF cell lines). Our unpublished data are in favor
of the ﬁrst hypothesis. In etoposide-treated REtsAF cells, zVAD-fmk
increased p53 stability and phosphorylation (Ser-15) as well as
puma trans-activation (data not shown). These data suggest that the
effect of zVAD-fmk on etoposide-induced cell death is located down-
stream of p53 regulation in MEFs. We thus focused our study on mi-
tochondrial events and showed that zVAD-fmk accelerates the loss
of ΔΨm, cytochrome c release in the cytosol and caspase-9 activation
in etoposide-treated 3T9 MEFs (Figs. 1, 4, 5). We also showed that Bax
and Bak are required for etoposide-induced loss of ΔΨm in the ab-
sence or presence of zVAD-fmk, in contrast to ROS production that
was not detected in MEF cells (Fig. 3). These data let us hypothesize
that zVAD-fmk could induce an ampliﬁcation loop of an etoposide-
induced cell death at the mitochondrial level in MEFs.
Two presumed broad caspase inhibitors, zVAD-fmk and Q-VD-Oph,
increased etoposide-induced loss of ΔΨm in 3T9 MEFs (Figs. 1 and 6),
suggesting that both drugs act via the regulation of caspase activities.
The study of caspase activities by analysis of their cleavage, activity and/
or the cleavage of speciﬁc targets after etoposide treatment in MEFs(Figs. 5, 6, 7) showed that: (i) zVAD-fmk classically inhibited effector
caspases (i.e. caspase-3, -6 and ‐7), (ii) zVAD-fmk did not inhibit the ini-
tiator caspase-9 and in contrast induced an increase of the active forms of
this caspase, and (iii) Q-VD-OPh induced an accumulation of auto-
cleaved caspase-9. One hypothesis to explain these data is that the cata-
lytic site of the proform and the auto-cleaved form of caspase-9 could
not be accessible to zVAD-fmk, and to Q-VD-OPh, due to their integration
into the apoptosome and/or post-translational modiﬁcations (such as
phosphorylation). Indeed, the activation of caspase-9 and its regula-
tions are quite complex [11,16,30–34]. Caspase-9 is activated through
autocatalytic intra-chain cleavages into the apoptosome, and at least
two cleavages are involved in the generation of mature caspase‐9. The
pro-, auto-cleaved andmature forms present caspase activity. However,
conformational and catalytic speciﬁcities of these forms differ. Two pre-
vious reports have shown that zVAD-fmk does not inhibit the auto-
cleavage of procaspase‐9while it inhibits procaspase-3 cleavage byma-
ture caspase‐9 [32,35], suggesting that zVAD-fmk inhibits only mature
forms of caspase‐9. In the presence of etoposide, zVAD-fmk inhibited
neither the auto-cleavage of procaspase‐9 nor the processing of
procaspase‐3 by caspase‐9, suggesting that zVAD-fmk does not inhibit
any of the different forms of caspase-9 in MEFs. zVAD-fmk inhibited
the last processing step of caspase‐3 cleavage, which requires caspase-
3 activity and not caspase-9 activity. The increase in both auto-
cleaved caspase‐9 level and caspase‐9 activity could be the result of
an increase in the auto-cleavage process and/or the result of an inhibi-
tion of the degradation of cleaved caspase-9. zVAD-fmk increases mito-
chondrial membrane depolarization and cytochrome c release
suggesting that it can result in an increase at the cell level in
apoptosome activity and thus in an increase of auto-cleaved caspase-9
levels in the presence of zVAD-fmk. However, we cannot exclude the
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and that accumulation of auto-cleaved caspase-9 could result in part
from this regulation. Interactions between cell death and proteasomal
degradation were previously characterized [35,36]. In collaboration
with Isabelle Petropoulos (Université Pierre et Marie Curie, UR4 «
Vieillissement, Stress et Inﬂammation », Paris), we studied proteasomal
activities (in particular, chymotrypsin-like, post-glutamic hydrolase
and trypsin-like activities) in 3T9 MEFs in the absence or in the pre-
sence of etoposide and zVAD-fmk. No signiﬁcant modiﬁcation of these
activities was detected in the presence of etoposide+/−zVAD-fmk, in
contrast towhatwas observed in TNFα-treated 3T9MEFs (unpublished0
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depolarization. The correlation between cleaved caspase-9 level
and loss of ΔΨm suggests that caspase-9 induces mitochondrial
membrane depolarization and an ampliﬁcation loop of the cell
death process induced by etoposide. Thus, although caspase-9 is
not required for etoposide-induced loss of ΔΨm in MEFs cells,
caspase-9 is required for the ampliﬁcation of this process by zVAD-fmk. Such a positive feedback loop at the mitochondrial level could
involve a cleavage of an anti-apoptotic member of the Bcl‐2 family
as described in other systems [37,38].
In conclusion, we demonstrate here for the ﬁrst time that caspase-9,
which is up-regulated by zVAD-fmk, induces an ampliﬁcation loop at
the mitochondrial level of the cell death process induced by etoposide
in mouse embryonic ﬁbroblasts.
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